Noretreat,

Keep in mind that enrollment is a part of the equation, and at the AGM Update we were told that enrollment is running a little behind. The trial was originally designed to acheive 30% MACE reduction in the apabetalone group and had an original 125 MACE event futility analysis trigger estimated to be mid-2017. I appreciate your efforts, but I think it will be difficult to determine if any potential delay past mid-2017 for the futility analsyis is due to enrollment or degree of MACE reduction. Just my opinion. Don't let me discourage you from trying, but just wanted to make sure you factored enrollment into your numbers.

BearDownAZ